Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

International Journal of Cancer

Volumn 79, Issue 5, 1998, Pages 449-454

  Chambers, Setsuko K ^a   Ivins, Christina M ^a   Carcangiu, Maria L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EPITHELIUM; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031692103     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0     Document Type: Article

References (25)

1. BLASI, F., Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays, 15, 105-111 (1993).
2. BOUCHET, C., SPYRATOS, F., MARTIN, P.M., HACÉNE, K., GENTILE, A. and OGLOBINE, J., Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Brit. J. Cancer, 69, 398-405 (1994).
3. BRUCKNER, A., FILDERMAN, A.E., KIRCHHEIMER, J.C., BINDER, B.R. and H.G. REMOLD., Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res., 52, 3043-3047 (1992).
4. CAJOT, J.F., BAMAT, J., BERGONZELLI, G.E., KRUITHOF, E.K.O., MEDCALF, R.L., TESTUZ, J. and SORDAT, B., Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. nat. Acad. Sci. (Wash.), 87, 6939-6943 (1990).
5. CASSLEN, B. and ASTEDT, B., The plasminogen activating system in ovarian carcinomas. Fibrinolysis, 6, 65-69 (1992).
6. CHAMBERS, S.K., GERTZ, R.E., IVINS, C.M. and KACINSKI, B.M., The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer, 75, 1627-1633 (1995a).
7. CHAMBERS, S.K., IVINS, C.M. and CARCANGIU, M.L., Expression of plasminogen activator Inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor, related to the actions of CSF-1. Int. J. Cancer, 74, 571-575 (1997a).
8. CHAMBERS, S.K., KACINSKI, B.M., IVINS, C.M. and CARCANGIU, M.L., Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted to a protective effect of stromal CSF-1. Clin. Cancer Res., 3, 999-1007 (1997b).
9. CHAMBERS, S.K., WANG, Y., GERTZ, R.E. and KACINSKI, B.M., Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res., 55, 1578-1585 (1995b).
10. GANESH, S., SIER, C.F.M., GRIFFIOEN, G., VLOEDGRAVEN, H.J.M., DE BOER, A., WELVAART, K., VAN DE VELDE, C.J.H., VAN KRIEKEN, J.H.J.M., VERHEIJEN, J.H., LAMBERS, C.B.H.W. and VERSPAGET, H.W., Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54, 4065-1071 (1994).
11. GRIS, J-C., SCHVED, J-F., MARTY-DOUBLE, C., MAUBOUSSIN, J-M. and BALMES, P., Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest, 104, 8-13 (1994).
12. GRONDAHL-HANSEN, J., CHRISTENSEN, I.J., ROSENQUIST, C., BRUNNER, N., MOURIDSEN, H.T., DANO, K. and BLICHERT-TOFT, M., High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521 (1993).
13. HAMILTON, J.A., WHITTY, G.A., STANTON, H., WOJTA, J., GALLICHIO, M., MCGRATH, K. and IANCHES, G., Macrophage colony-stimulating factor and granulocyte- macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood, 82, 3616-3621 (1993).
14. KACINSKI, B.M., CARTER, D., MITTAL, K., YEE, L.D., SCATA, K.A., D'ONOFRIO, L., CHAMBERS, S.K., WANG, K., YANG-FENG, T., ROHRSCHNEIDER, L.R. and ROTHWELL, V.M., Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Amer. J. Pathol., 137, 135-147 (1990).
15. KACINSKI, B.M., SCATA, K.A., CARTER, D., YEE, L.D., SAPI, E., KING, B.L., CHAMBERS, S.K., JONES, M.A., PIRRO, M.H., STANLEY, E.R. and ROHRSCHNEIDER, L.R., FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene, 6, 941-952 (1991).
16. KOBAYASHI, H., FUJISHIRO, S. and TERAO, T., Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res., 54, 6539-6548 (1994).
17. KOBAYASHI, H., OHI, H., SUGIMURA, M., SHINOHARA, H., FUJII, T. and TERAO, T., Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res., 52, 3610-3614 (1992).
18. KUHN, W., PACHE, L., SCHMALFELDT, B., DETTMAR, P., SCHMITT, M., JÄNICKE, F. and GRAEFF, H., Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol., 55, 401-409 (1994).
19. OKEN, M.M., CREECH, R.H., TORMEY, D.C., HORTON, J., DAVIS, T.E., MCFADDEN, E.T. and CARBONE, P.P., Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer. J. clin. Oncol., 5, 649-655 (1982).
20. PRICE, F.V., CHAMBERS, S.K., CHAMBERS, J.T., CARCANGIU, M.L., SCHWARTZ, P.E., KOHORN, E.I., STANLEY, E.R. and KACINSKI, B.M., CSF-1 concentration in primary ascites of ovarian cancer is a significant predictor of survival. Amer. J. Obstet. Gynecol., 168, 520-527 (1993).
21. PYKE, C., KRISTENSEN, P., RALFKIAER, E., ERIKSEN, J. and DANØ, K., The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res., 51, 4067-4071 (1991).
22. SCHMALFELDT, B., KUHN, W., REUNING, U., PACHE, L., DETTMAR, P., SCHMITT, M., JÄNICKE, F., HOFLER, H. and GRAEFF, H., Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55, 3958-3963 (1995).
23. SCHOLL, S., BASCOU, C.H., MOSSERI, V., OLIVARES, R., MAGDALENAT, H., DORVAL, T., PALANGI, T., VALIDARE, P., POUILLART, P. and STANLEY, E.R., Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Brit. J. Cancer, 62, 342-346 (1994).
24. SPEISER, P., MAYERHOFER, K., KUCERA, E., ROCH, G., MITTELBOCK, M., GITSCH, G. and ZEILLINGER, R., pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters. Anticancer Res., 17, 679-684 (1997).
25. VAN DER BURG, M.E.L., HENZEN-LOGMANS, S.C., BERNS, E.M.J.J., VAN PUTTEN, W.L.J., KLIJN, J.G.M. and FOEKENS, J.A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer, 69, 475-479 (1996).